Salute e Benessere
Sectra's three-month interim report 2024/2025: Increased recurring revenue led to a strong first quarter
"The first quarter was dominated by deliveries of previously ordered customer projects. Additional hospitals have gone live with our cloud-based services for medical imaging and we have delivered several products for secure communication to defense forces and authorities.
"In Business Innovation, the launch of the new genomics IT module marked a major milestone during the quarter. Cancer diagnostics based on genetic information (genomics) is developing quickly and has, until this point, lacked effective IT support for high production. Our new offering strengthens Sectra's position in integrated diagnostics for cancer care, an area that we have seen grow in importance when healthcare providers evaluate potential suppliers.
"Financially speaking, we had a stable beginning to the fiscal year. Positive performances in all operating areas contributed to our highest-ever sales and operating profit figures for a first quarter. To some extent, this is because increased recurring revenue has helped to even out the results between quarters."
Read the attached interim report for further CEO comments and information.
Torbjörn Kronander, President and CEO of Sectra AB, and
Jessica Holmquist , CFO of Sectra AB, will present the financial report and answer questions. The presentation will be held in English.
Time: September 6, 2024 at
10:00 a.m. CEST
Follow live or listen to the recording afterward:
https://investor.sectra.com/Q1report2425
Dr. Torbjörn Kronander, President and CEO, Sectra AB, +46 (0) 705 23 52 27
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/sectras-three-month-interim-report-20242025-increased-recurring-revenue-led-to-a-strong-first-quarter-302240386.html